查詢結果分析
相關文獻
- 磷酸雙脂酶-5抑制劑的新發展
- 淺談良性攝護腺增生之中西醫藥物治療
- Free-to-total Serum Prostate Specific Antigen Ratio in Chinese Men
- Videourodynamic Evaluation of the Pathophysiology of Lower Urinary Tract Symptoms in Neurologically Intact Women
- Changes of Serum Prostate-Specific Antigen Before and After Transurethral Vaporization of Prostate for Benign Prostatic Hyperplasia
- Early Experience with High Intensity Focused Ultrasound for the Treatment of Benign Prostate Hyperplasia
- 護理一位攝護腺肥大病患的經驗
- 良性攝護腺肥大病患之尿流動力學檢查
- 良性攝護腺肥大之流行病學及病程
- 良性攝護腺肥大之臨床及基礎研究
頁籤選單縮合
題名 | 磷酸雙脂酶-5抑制劑的新發展=New Era for Phosphodiesterase-5 Inhibitors |
---|---|
作者姓名(中文) | 張鐳[王欝]; 吳承誌; 蔡敏鈴; | 書刊名 | 藥學雜誌 |
卷期 | 29:4=117 2013.12[民102.12] |
頁次 | 頁69-72 |
分類號 | 418.22 |
關鍵詞 | 良性攝護腺肥大; 下尿路症狀; 磷酸雙脂酶-5抑制劑; Benign prostatic hyperplasia; Lower urinary tract symptoms; Phosphodiesterase-5 inhibitors; |
語文 | 中文(Chinese) |
中文摘要 | 良性攝護腺肥大 (benign prostatic hyperplasia, BPH)為一膀胱基質細胞 (stromal cell)及平滑肌增生 (proliferation)之現象。下尿路症狀 (lower urinary tract symptoms, LUTS)可能由各種疾病造成,以良性攝護腺肥大為最常見的原因。 LUTS的病理機制相當複雜,與一氧化氮、發炎、雄性素、自主神經及血管硬化有關。實驗室研究證實,磷酸雙脂酶 -5抑制劑 (phosphodiesterase-5 inhibitors, PDE-5 inhibitors)的藥理活性能有效抑制上述病理因子的持續惡化;臨床試驗更進一步確立 PDE-5 inhibitors能有效改善症狀。 Tadalafil為近期唯一通過美國與歐洲核准於治療良性攝護腺肥大之藥品。囿於證據力不足,該類藥品的使用仍較為侷限。 |
英文摘要 | Prostatic stromal cells and smooth muscle proliferation contribute to benign prostatic hyperplasia (BPH). Lower urinary tract symptoms, abbreviated as LUTS, can be induced by several diseases. BPH is the most important and frequent cause. The pathological mechanism of LUTS remains complicated, involving nitric oxide, inflammation, androgen, autonomic nerve and atherosclerosis. The pre-clinical data and evidence prove that pharmacological activities of PDE5 inhibitors can effectively inhibit the progression of factors. Robust results were also promulgated by many of clinical trials. Recently, tadalafil is the only drug of PDE-5 inhibitors approved by U.S. and Europe to treat BPH. However, it is restricted to the limited and equivocal results, application of PDE-5 inhibitors remains conservative. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。